Page last updated: 2024-11-13

arginine butyrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

arginine butyrate: protects against lethal effect of encelphalomyocarditis virus in mice; also used to administer butyrate to stimulate globin gene expression in beta-thalassemia and sickle cell anemia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23622962
MeSH IDM0102629

Synonyms (15)

Synonym
arginine butyrate
vx 105
l-arginine butanoate
l-arginine, monobutanoate
l-arginine, butanoate (3:4)
l-arginine butyrate (3:4)
hqk-1004
ik8s1p79mu ,
80407-72-3
unii-ik8s1p79mu
arginine butanoate [who-dd]
vx-105
DTXSID60942437
Q27280766
(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Arginine butyrate treatment improved grip strength and decreased fibrosis in the gastrocnemius muscle, but did not produce significant improvement in muscle and cardiac histology, heart function, behavioral measurements, or serum creatine kinase levels."( Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy.
Becker, M; Bossi, L; Cha, HJ; de la Porte, S; Escolar, DM; Farajian, V; Francia, D; Gernapudi, R; Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Nagaraju, K; Pandey, GS; Partridge, T; Pistilli, E; Rawat, R; Sali, A; Spurney, CF; Zerr, P, 2010
)
1.36

Pharmacokinetics

ExcerptReferenceRelevance
" In mice and rabbits, the half-life is less than 5 min."( Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts.
Baillet, J; Brazier, M; Cerutti, I; Chany, C; Daniel, P; Desmet, G; Pieri, F; Tardivel, I, 1989
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Additional studies are needed to determine minimum effective dosage and interval, what proportion of patients respond, and whether the agent can prevent neurologic degeneration."( Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy.
Aron, A; McGovern, MM; Perrine, SP; Wasserstein, MP, 2003
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (22.73)18.7374
1990's17 (38.64)18.2507
2000's8 (18.18)29.6817
2010's9 (20.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.28 (24.57)
Research Supply Index3.93 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (18.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (8.70%)5.53%
Reviews6 (13.04%)6.00%
Case Studies4 (8.70%)4.05%
Observational0 (0.00%)0.25%
Other32 (69.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Trial of Arginine Butyrate for Treatment of Refractory Leg Ulcers in Sickle Cell Disease or Beta Thalassemia [NCT00004412]Phase 223 participants (Actual)Interventional1997-09-30Completed
A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders [NCT00992732]Phase 21 participants (Actual)Interventional2010-05-31Terminated
A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies [NCT00917826]Phase 21 participants (Actual)Interventional2008-09-30Terminated
[NCT00006136]Phase 215 participants Interventional1999-03-31Completed
A PHASE I TRIAL OF BUTYRATE AND GANCICLOVIR IN EBV-ASSOCIATED MALIGNANCIES [NCT00006340]Phase 10 participants Interventional1994-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00004412 (2) [back to overview]% Ulcers Which Completely Healed in Each Group, After 3 Months
NCT00004412 (2) [back to overview]Healing Defined as a Decrease in Ulcer Area by at Least 25% of the Initial Area

% Ulcers Which Completely Healed in Each Group, After 3 Months

Control Arm: given option to crossover to Treatment Arm if, ulcers have not closed after 12 weeks standard local care alone. (NCT00004412)
Timeframe: two additional courses of 8 week cycles

Interventionpercentage of completely healed ulcers (Number)
Standard Local Care Dressing8
Arginine Butyrate31

[back to top]

Healing Defined as a Decrease in Ulcer Area by at Least 25% of the Initial Area

"Treatment Arm: The AB is given as an IV infusion at 500 mg/kg over 6-9 hrs. 5 days per week for 12 weeks. After 12 weeks of therapy, if he ulcer has decreased by 25% , the AB may be continued for additional 8 weeks (twice) or, until ulcer closes plus 2 weeks, additionally.~Ulcers photographed, traced, and ulcer areas calculated by computerized planimetry." (NCT00004412)
Timeframe: participants were followed for an average of 3 months

Interventionpercentage of healed ulcers (Number)
Standard Local Care Dressing24
Arginine Butyrate78

[back to top]